In the international SUMMIT trial, adults with heart failure preserved ejection fraction (HFpEF) and obesity taking ...

Nearly all on tirzepatide reverted to normoglycemia ... people who use diabetes medications — we have a structure of chronic ...

Tirzepatide by Eli Lilly reduces heart failure risk in adults with HFpEF and obesity, showing promising results for both ...

In an earlier analysis of the SURMOUNT-1 trial, tirzepatide was shown to provide substantial and sustained reductions in body weight in persons with obesity over a 72-week period. Here ...

Following an impressive data drop this summer highlighting the potential for Eli Lilly’s tirzepatide to stave off progression ...

Eli Lilly and Co. (LLY) has released detailed findings from the Phase 3 SUMMIT trial, demonstrating that tirzepatide significantly ...

Payers and employers have tightened access to the glucagon-like peptide-1 receptor agonist class once these therapies became ...

Findings at week 176 demonstrated that among prediabetic patients treated with tirzepatide (efficacy estimand; pooled doses of 5mg, 10mg, 15mg), 98.8% remained diabetes free. Detailed results were ...

Eli Lilly has reported comprehensive outcomes from the SURMOUNT-1 study of tirzepatide (Zepbound and Mounjaro) for treating pre-diabetic and obese individuals. Spanning 176 weeks of treatment ...